Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics' stock has increased by 235.54% over the past six months. In November 2025, the company reported positive interim data for LX2006, announced progress towards a pivotal study, and secured $154 million in financing, also reporting reduced net loss and a strong cash position in its Third Quarter 2025 financial results. The FDA approved the analytical comparability report for LX2006. Cantor Fitzgerald initiated coverage with an "Overweight" recommendation. In October 2025, the company closed a public offering and concurrent private placement, with the stock rising due to progress in its heart disease treatment programs. Chardan Capital maintained a "Buy" recommendation, increasing the price target by 19.77% to $21.29. In July 2025, the company received Breakthrough Designation for its gene therapy. Analysts have a "Strong Buy" consensus rating for LXEO stock, with an average 12-month price target of $18.22.

As a clinical-stage genetic medicine company without commercialized products or services, information regarding demand seasonality is not applicable to Lexeo Therapeutics at this stage of its development.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing therapies for hereditary and acquired diseases, particularly genetically defined cardiovascular diseases and a subgroup of Alzheimer's disease. The company's pipeline includes LX2006, an AAVrh10-based gene therapy candidate in Phase 1/2 clinical trials for Friedreich's ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate in Phase 1/2 trials for PKP2-ACM; and LX2021, a gene therapy candidate in preclinical development for inherited cardiac muscle disorders and APOE4 homozygous patients with Alzheimer's disease.

Lexeo Therapeutics, Inc. is headquartered in New York, NY, United States, with a primary focus on addressing hereditary and acquired diseases with high unmet needs in the United States.

Lexeo Therapeutics has maintained a positive brand reputation in the past year due to favorable developments in its clinical programs. The company has received positive media attention for its progress in heart disease treatments and for securing Breakthrough Therapy Designations for its rare disease treatments. Analyst upgrades and optimistic forecasts have also contributed to a positive perception of the company.

Lexeo Therapeutics, Inc. has a diverse ownership structure, with institutional investors holding approximately 25.26% to 34.96% of the stock, including major holders like Janus Henderson Group Plc and BlackRock, Inc. Insiders own about 0.86% of the stock, while retail investors hold approximately 64.18%. Michael Rockefeller owns the most shares among individual investors.